ArticleRevista peruana de medicina experimental y salud publica2025
Parasite genotypes and host immune mediators in primary and recurrent episodes of vivax Malaria in Colombia.
Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVES.: To identify Plasmodium vivax genotypes in the pregnant and non-pregnant population and explore their association with immune mediators. MATERIALS AND METHODS.: Two cohorts of patients with uncomplicated vivax malaria were followed for 120 days in Puerto Libertador and Tierralta, Cordoba, Colombia: 41 pregnant women and 46 non-pregnant individuals, all treated with standard treatment. Parasite genotypes (microsatellites Pv3.27, Pv3.502, and Pv1.501) and the expression of host immune mediators (IL-13, IL-10, TNF-alpha, IFN-gamma, IL-8, TGF-beta, Fox-P3, PD-L1) were compared between primary and recurrent infections. RESULTS.: The frequency of recurrences was higher in pregnant women (41.6%) than in non-pregnant individuals (8.7%). Parasite genetic diversity was higher in pregnant women, although without exclusive alleles. Recurrences were genetically homologous (same alleles) in only 23% and 33% of cases in pregnant and non-pregnant individuals, respectively. Regarding immune mediators, only Fox-P3 expression varied significantly in pregnant women, with higher expression in the primary episode than in the recurrent one. CONCLUSIONS.: Pregnant women are exposed to a high frequency of vivax malaria recurrences, with high parasite genetic variation, which may affect the development of effective protective immunity and favor adverse obstetric outcomes, both maternal and neonatal. These findings raise the need to strengthen and optimize prevention and treatment actions for vivax malaria during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.